Recent studies have shown that nafamostat mesilate potentiated gemcitabine anti-tumor effect by inhibiting gemcitabine induced NF-kB activation in pancreatic cancer [28], [29]. Here, NFKB1 is linked to familial pancreatic carcinoma.